Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Poly-ICLC for Progressive LGG in Pediatric NF1
NCT04544007Phase 2Terminated
- Sponsor
- University of Alabama at Birmingham
- Start
- Feb 2022
- Primary completion
- Jan 2024
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
A Phase 2 trial of poly iclc in glioma, sponsored by University of Alabama at Birmingham. Started Feb 2022; status: terminated.
02
Drugs
poly iclc
03
Conditions
glioma
Beyond the preview
Go deeper on NCT04544007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04544007.